lilly retatrutide trial Lilly's triple agonist achieves 16.8% weight loss in phase 3 A Study of Retatrutide (LY3437943)

Usage disclaimer: A subjects dosage and administration should be determined by a qualified healthcare professional

doi: 10.1016/j.diabet.2019.101117 33 IkushimaIJensenLFlintANishidaTZachoJ

Mounjaro is a dual receptor agonist that binds to both the GLP-1 receptor and the GIP receptor

[36] Semaglutide-associated kidney injury | Clinical Kidney Journal | Oxford Academic. Accessed: Nov

Most GLP-1 agonists are administered safely as subcutaneous injections, meaning they are injected into the fatty layer of tissue just under the skin

Dual GLP1 and GIP agonists Tirzepatide is a once weekly, subcutaneous, unimolecular dual RA (GLP-1 and GIP) which has comparable GIP receptor binding affinity to native GIP and 5 times lower GLP-1 receptor affinity than that of native GLP-1